Loading

Sensus Healthcare Announces the Sale/Install of its 500th Unit

Click to Download PDF

Mid-Atlantic Skin Surgery Institute in Maryland acquires a second SRT system

BOCA RATON, Fla. (April 13, 2021) – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced the installation of its 500th unit, achieving a key milestone set forth when the Company began operations in February 2011.  This milestone was met on April 5, 2021 when an SRT-100™ system was shipped to the Mid-Atlantic Skin Surgery Institute, led by George Verghese, M.D. who is opening his second office office in Maryland.

Dr. Verghese is a board-certified dermatologist who, in addition to maintaining his private practice, is an Assistant Clinical Professor of Dermatology at Howard University College of Medicine and former Mohs surgeon for the Veterans Affairs Medical Center in Washington, DC.  This SRT (superficial radiation therapy) system is the second Dr. Verghese has purchased, for a new office in his growing practice. He purchased his first Sensus SRT system in 2014, seven years ago.

“We are delighted to count Dr. Verghese among the growing number of distinguished clinicians who continues to see the SRT technology as an integral part of his growing practice,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “We pride ourselves in being associated with physicians who put their patients first and make SRT available to those with non-melanoma skin cancer or keloids.  SRT is extremely efficacious, safe and non-invasive, making it a highly attractive treatment option for many patients.

“At the outset, our goal was to have 500 systems installed. In reaching this milestone, we feel we can add the next 500 units in half that time,” Mr. Sardano continued.  “Given growing awareness among clinicians as well as patients of the important features and benefits of our products, along with improved Medicare reimbursement for SRT treatments, we are optimistic this goal will be achieved.”

“SRT treatments have revolutionized the way that we offer patient solutions regarding skin cancer diagnosis,” commented Dr. Verghese. “Mid-Atlantic Skin is thrilled about acquiring our second SRT-100 device and Sensus’s 500th worldwide offering skin cancer superficial radiation therapy to our Southern Maryland patient community.

“Patients desire options and many are surprised to learn that a non-surgical option for skin cancer is available, especially if the patient comes from another dermatology practice without SRT. In our experience, this innovation demonstrates excellent patient outcomes and we highly recommend Sensus as a preferred partner,” Dr. Verghese added.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted Directional Anisotropic Radiation Therapy (ART) and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, ”forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors:  our ability to achieve and sustain profitability; market acceptance of our product lines; our ability to successfully commercialize our products; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future; our ability to expand, manage and maintain our direct sales and marketing organizations; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our current reliance on third party manufacturers and sole- or single-source suppliers, as well as our ability to successfully transition manufacturing of our products in-house; our ability to reduce the per unit manufacturing costs; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in Sensus Healthcare’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our “Cautionary Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

Contact:

LHA Investor Relations

Kim Sutton Golodetz

212-838-3777

kgolodetz@lhai.com

Share to:

Contact Us

Fill out the form below to find out more!